Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.32 |
| ▸ | CLK1 | P49759 | 2/20 | 0.32 |
| ▸ | CLK2 | P49760 | 2/20 | 0.32 |
| ▸ | CLK3 | P49761 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648813 | 1.00 | MME (0.36) | MMEPOLBMIFCA14TAS1R3 | |
| SCHEMBL29035998 | 1.00 | MME (0.36) | MMEPOLBMIFCA14TAS1R3 | |
| SCHEMBL4328211 | 1.00 | MME (0.36) | MMEPOLBMIFCA14TAS1R3 | |
| SCHEMBL1278884 | 0.83 | ALDH1A1 (0.33) | — | |
| SCHEMBL6224340 | 0.83 | MME (0.35) | MMEPOLBMIFCA14TAS1R3 | |
| SCHEMBL13955558 | 0.83 | MME (0.35) | MMEPOLBMIFCA14TAS1R3 | |
| SCHEMBL23423424 | 0.82 | MIF (0.33) | MIFCA14CA12 | |
| SCHEMBL18531966 | 0.81 | MIF (0.33) | MIFCA14CA12CA7CA9 | |
| SCHEMBL20630584 | 0.80 | CTSK (0.36) | POLBCA7 | |
| SCHEMBL12486130 | 0.80 | CTSK (0.36) | POLBCA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232130-A | APN and AKT double-target-point inhibitor and preparation method and application thereof | 山东大学 | 2022-10-25 | — | — | CN | claimed |
| US-12275710-B2 | Compound, curing agent composition, resin composition, coating composition and resin cured product | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-04-15 | — | — | US | disclosed |
| EP-3774961-B1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2025-01-15 | — | — | EP | disclosed |
| CN-118215651-A | Method for producing isocyanate compound, method for producing urethane compound, method for recovering amine compound, and isocyanate composition | 旭化成株式会社 | 2024-06-18 | — | — | CN | disclosed |
| US-20240150515-A1 | Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers | COVESTRO DEUTSCHLAND AG (DE) | 2024-05-09 | — | — | US | disclosed |
| CN-117897386-A | Benzopyran derivatives and uses thereof | 斯帕克生物制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-115232130-B | APN and AKT double-target inhibitor and preparation method and application thereof | 山东大学 | 2024-01-12 | — | — | CN | disclosed |
| EP-4298140-A1 | LOW VISCOSITY CATALYST COMPOSITIONS FOR PRODUCING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-01-03 | — | — | EP | disclosed |
| CN-116917364-A | Low viscosity catalyst composition for producing isocyanurate polymers | 科思创德国股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6281363-B1 | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; AUTOIMMUNE DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-08-28 | — | — | US | disclosed |
| EP-1037905-A1 | ANTIPICORNAVIRAL COMPOUNDS AND METHODS FOR THEIR USE AND PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-2000035885-A1 | CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| US-5962487-A | PICORNAVIRAL 3C PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999031122-A9 | ANTIPICORNAVIRAL COMPOUNDS AND METHODS FOR THEIR USE AND PREPARATION | AGOURON PHARMA (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999031122-A1 | ANTIPICORNAVIRAL COMPOUNDS AND METHODS FOR THEIR USE AND PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| CN-1039026-A | The method for preparing trinucleated 3-oxo-propanenitrile derivatives | ERBA CARLO SPA (IT) | 1990-01-24 | — | — | CN | disclosed |
| EP-0207358-A2 | Growth-promoting agent | BAYER AG (DE) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275710-B2 | Compound, curing agent composition, resin composition, coating composition and resin cured product | CARM1, KDM2B, UFM1 | MME 1671/4885POLB 3419/4885MIF 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.